PSNL
Personalis, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$17.20
+2.20%Aug 4, 2026, 22:16 UTC
Personalis reported a Q2 2026 net loss of $0.30 per share, missing the Zacks Consensus Estimate of a $0.25 loss and wider than the $0.23 loss a year earlier.
Source:Aug 4, 2026, 18:04 UTC
Wohl & Fruchter LLP announced an investigation into the fairness of the proposed acquisition of Personalis, Inc. by Tempus AI, Inc. for $16.25 per share.
Source:Jul 20, 2026, 12:31 UTC
TEMPUS AI will acquire PERSONALIS at $16.25 per share, with the transaction expected to close between late 2026 and early 2027.
Jul 14, 2026, 10:00 UTC
Personalis, Inc. announced it has received UKCA marking for its NeXT Personal Dx test, enabling clinical use in Great Britain.
Source:Jun 9, 2026, 10:00 UTC
Personalis obtained CE-IVD marking for its EDTA Blood Collection Kit and cfDNA Blood Collection Kit under the EU IVDR regulation.
Source: